Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions
Key Insights Silence Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 54% of the business is held by the top
Silence Therapeutics Announces JAMA Publication Of Additional APOLLO Phase 1 Data For Zerlasiran In Subjects With Elevated Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision
Brokers Are Upgrading Their Views On Silence Therapeutics Plc (NASDAQ:SLN) With These New Forecasts
Shareholders in Silence Therapeutics plc (NASDAQ:SLN) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased thei
Analysts Are Upgrading Silence Therapeutics Plc (NASDAQ:SLN) After Its Latest Results
Silence Therapeutics Plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc (NASDAQ:SLN) reported a loss for 2023 on Wednesday. The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago, a
Silence Therapeutics Announces Topline 36-Week Data From Ongoing Phase 2 Study of Zerlasiran in Patients With High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
Broker Revenue Forecasts For Silence Therapeutics Plc (NASDAQ:SLN) Are Surging Higher
Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 26% But Growth Is Lacking
Silence Therapeutics plc (NASDAQ:SLN) shares have continued their recent momentum with a 26% gain in the last month alone. Looking back a bit further, it's encouraging to see the stock is up 72% in
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect?
Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 65% But Growth Is Lacking
Silence Therapeutics plc (NASDAQ:SLN) shares have had a really impressive month, gaining 65% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the loss
Virpax Pharmaceuticals CEO and Chairman Resigns on Ongoing Litigation
Silence Therapeutics Plc (NASDAQ:SLN) Q4 2022 Earnings Call Transcript
Silence Therapeutics Plc (NASDAQ:SLN) Short Interest Down 17.1% in February
Silence Therapeutics plc (NASDAQ:SLN – Get Rating) was the target of a large drop in short interest in February. As of February 28th, there was short interest totalling 14,500 shares, a drop of 17.1%
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
BVF Inc. IL Has $14.89 Million Stock Position in Silence Therapeutics Plc (NASDAQ:SLN)
BVF Inc. IL raised its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN – Get Rating) by 126.3% in the third quarter, according to the company in its most recent Form 13F filing with the Se
SG Americas Securities LLC Sells 2,500 Shares of Silence Therapeutics Plc (NASDAQ:SLN)
SG Americas Securities LLC lessened its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN – Get Rating) by 2.5% during the 3rd quarter, according to its most recent disclosure with the SEC.
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?
No Data